ZZZhu Zhang

Zhu Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhu Zhang has a total of 262 co-authors. Here are the top co-authors by number of shared publications:

  • Zhenguo Zhai

    China-Japan Friendship Hospital

    8 shared publications
  • Shuai Zhang

    National Centre for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Centre for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Centre of Respiratory Medicine, China-Japan Friendship Hospital , 100029 Beijing

    5 shared publications
  • Wanmu Xie

    National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China

    4 shared publications
  • Bingzhang Zou

    Department of Respiratory and Critical Care Medicine, National Clinical Research Center of Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital Beijing, China

    3 shared publications
  • Chen Wang

    National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine China‐Japan Friendship Hospital Beijing China

    3 shared publications
  • Dingyi Wang

    China‐Japan Friendship Hospital

    3 shared publications

Latest Publications

  • Open Access

    Targeting ALDOA Lactylation Reverses Vascular Remodeling in Pulmonary Hypertension by Disrupting Actin Polymerization and YAP Activation

    by Xiaoxun Huang, Jincheng Zhang, Qingye Zeng, Minghui Lin, June Bai, Huazhuo Feng, Jing Liu, Zhao Sha, Tongyu Peng, Yicheng Lv, et al.

    BACKGROUND: Maladaptive vascular remodeling is a hallmark of pulmonary hypertension (PH), and therapeutic strategies directly targeting the pathological activity of smooth muscle cells remain limited. Metabolic and epigenetic dysregulation are established drivers of PH, and lysine lactylation has emerged as a novel posttranslational modification implicated in diverse diseases; however, its direct contribution to PH progression remains undefined. METHODS: Integrated lactylomic and proteomic profiling was performed in hypoxic human pulmonary arterial smooth muscle cells. The functional role of ALDOA (aldolase A) lactylation at lysine 42 (K42) was assessed using site-specific mutant virus and smooth muscle cell-specific inducible ALDOA knockout mice in 2 established PH models: SU5416+hypoxia in mice and monocrotaline in rats. RESULTS: We identified ALDOA as a prominent lactylation target in hypoxic pulmonary arterial smooth muscle cells, with K42 lactylation consistently elevated in primary pulmonary arterial smooth muscle cells derived from PH rodent models and human PH tissues. Mechanistically, AARS1 (alanyl-tRNA synthetase 1)-mediated ALDOA K42 lactylation enhanced its binding to γ-actin, independent of glycolytic activity. This lactylation-enhanced interaction promoted F-actin polymerization and activated YAP (Yes-associated protein) signaling via LATS1 (large tumor suppressor kinase 1) inhibition, thereby driving pulmonary arterial smooth muscle cell proliferation and phenotypic switching. Moreover, YAP/TEAD4 (TEA domain transcription factor 4)-mediated transcriptional upregulation of AARS1 established a positive feedback loop reinforcing ALDOA K42 lactylation under hypoxia. In vivo, ALDOA inducible knockout or reconstitution with the lactylation-deficient K42R (lysine 42 mutant to arginine) mutant attenuated experimental PH progression, with suppressed F-actin/YAP activation and reduced vascular remodeling. Furthermore, competitive inhibition of lactylation through β‑alanine reduced ALDOA K42 lactylation and ameliorated vascular remodeling in ALDOA-overexpressing rodent PH models. Translationally, pharmacological disruption of the ALDOA/γ-actin interaction by raltegravir suppressed cytoskeletal reorganization and YAP signaling, mitigating PH progression in both mouse and rat models. CONCLUSIONS: AARS1-mediated ALDOA K42 lactylation drives pulmonary vascular remodeling through a mechanism independent of ALDOA’s catalytic activity, promoting F-actin polymerization and YAP activation. Precision targeting of this modification selectively inhibits pathological signaling while preserving metabolic homeostasis, highlighting a translational potential for precision intervention in PH.

  • Open Access

    Right Ventricular–Pulmonary Arterial Coupling by Serial TAPSE/sPAP: A Noninvasive Predictor for Clinical Outcomes in Chronic Thromboembolic Pulmonary Hypertension

    by Jing Wen, Ruzetuoheti Yiminniyaze, Yishan Li, Sugang Gong, Ling Zhu, Yuanhua Yang, Cheng Hong, Zhenwen Yang, Jun Wan, Xiaopei Cui, et al.

    The ratio of tricuspid annular plane systolic excursion to systolic pulmonary artery pressure (TAPSE/sPAP) is a noninvasive surrogate of right ventricular–pulmonary arterial coupling, but its value for dynamic risk stratification in chronic thromboembolic pulmonary hypertension (CTEPH) remains uncertain. This multicenter prospective cohort enrolled adults with CTEPH between 2016 and 2023. Patients were stratified by quartile‐based baseline TAPSE/sPAP cutoffs into < 0.15, 0.15 to 0.30, and > 0.30. The primary outcome was clinical worsening (CW) within 12 months, comprising all‐cause death, hospitalization for worsening pulmonary hypertension, escalation of pulmonary hypertension‐targeted therapy, or a > 30% increase in pulmonary vascular resistance. Associations were examined using Kaplan–Meier, Cox regression, and time‐dependent Cox analyses. Among 949 patients, 868 had follow‐up and 212 (24.4%) experienced CW during a median follow‐up of 10.3 months (interquartile range, 5.4–12.2 months). Lower baseline TAPSE/sPAP was associated with worse functional and hemodynamic profiles, and CW‐free survival differed across strata (log‐rank p = 0.004). Each 0.1‐unit increase in baseline TAPSE/sPAP was associated with lower CW risk (adjusted HR, 0.89; 95% CI, 0.79–0.99; p = 0.039). Among 593 patients with serial measurements, higher time‐updated TAPSE/sPAP (adjusted HR, 0.66; 95% CI, 0.52–0.83; p < 0.001) and greater improvement from baseline (adjusted HR, 0.81; 95% CI, 0.71–0.92; p = 0.002) were associated with lower subsequent CW risk. Lower TAPSE/sPAP identifies greater disease severity and CW risk in CTEPH. Serial TAPSE/sPAP may support noninvasive dynamic risk stratification and residual risk assessment during follow‐up.

  • Paradoxical Association of Body Mass Index With Occurrence and Mortality of Venous Thromboembolism in Hospitalized Patients: A National Hospital‐Based Cohort Analysis

    by Yuhao Li, Lei Xia, Huiwen Li, Dingyi Wang, Zhu Zhang, Guohui Fan, Yunxia Zhang, Shuai Zhang, Kaiyuan Zhen, Yuzhi Tao, et al.

    Background: The association between body mass index (BMI) and venous thromboembolism (VTE) occurrence and mortality is controversial. This study aimed to investigate the association of BMI with VTE occurrence and mortality and explore the consistency across age, sex, and medical specialty. Methods: This study included 3 199 526 inpatients at potential risk for VTE from a nationwide hospital‐based cohort. Participants were categorized as lean weight (BMI 2 ), normal weight (18.5 ≤BMI2 ), overweight (24.0 ≤BMI 2 ), and obesity (BMI ≥28.0 kg/m 2 ). Odds ratios (ORs) were calculated by logistic regression models. Results: In all participants, 59 002 (1.8%) developed VTE during hospitalization. After adjusting for the confounding factors, compared with normal weight, the risk of VTE occurrence reduced by 18% (odds ratio [OR], 0.82 [95% CI, 0.80–0.83]) in participants with overweight and 22% (OR, 0.78,[95% CI, 0.75–0.81]) in participants with obesity. The protective association of overweight/obesity was more pronounced in age ≥65 years, female patients, and surgery participants ( P for interaction P for interaction <0.05). Conclusion: An inverse association between BMI and VTE occurrence was observed among at‐risk inpatients, most pronounced in older, female, and surgical subgroups. Notably, obesity remained a risk factor in medical patients, whereas among surgical patients who developed VTE, it was paradoxically associated with lower mortality.

  • Open Access

    Thromboprophylaxis and HA-VTE Prediction

    by Mengyao Li, Zhu Zhang, Zhenguo Zhai, Bingzhang Zou

  • Performance of Western HA-VTE risk models in East Asian populations: a prospective multicenter study

    by Mengyao Li, Yuehan Duan, Zhaofei Chen, Jingrui Li, Yunfan Shi, Kaiyuan Zhen, Jing Ma, Lei Xia, Wei Wang, Qian Gao, et al.

    Hospital-associated venous thromboembolism (HA-VTE) causes significant morbidity, but risk prediction models are inconsistently validated, especially in non-Western populations. We prospectively validated 5 HA-VTE risk scores (Caprini, Padua, IMPROVE [International Medical Prevention Registry on Venous Thromboembolism], Kucher, and Intermountain) in a prospective multicenter cohort of 2948 adult inpatients from 17 Chinese hospitals. Symptomatic VTE events were recorded through 3 months of follow-up. The 90-day HA-VTE incidence was 2.54%. All 5 models showed moderate discrimination (area under the receiver operating characteristic curve [AUC], 0.726-0.759). Caprini, Padua, and Intermountain models did not differ significantly (DeLong test, P> .05). Caprini had the highest sensitivity (0.83) but classified 42.6% of patients as being at high risk. Padua and Intermountain favored specificity (0.75-0.81) with lower sensitivity (0.64-0.67). Clinical model selection should align with specific balances between sensitivity and utility. In surgical inpatients, Caprini performed best (AUC, 0.804; sensitivity, 0.90; negative predictive value, 1.00), although its more than 40 input variables limit practical use. Calibration was generally acceptable. Performance varied across subgroups. The prophylaxis subgroup showed attenuated performance, with reduced discrimination (eg, Caprini AUC decreased to 0.682) and less stable calibration. Western HA-VTE models have moderate predictive value in East Asian inpatient populations. Performance differs across subgroups. Local recalibration and development of simpler, population-specific scores are needed.


  • Prior Venous Thromboembolism Defines Distinct Genetic and Molecular Phenotypes in Chronic Thromboembolic Pulmonary Hypertension

    by Zhu Zhang, Mengjie Duo, Xiaofan Ji, Bingzhang Zou, Haobo Li, Kuangxun Li, Huiwen Li, Yuhan Li, Yishan Li, Xincheng Li, et al.

    BACKGROUND: Chronic thromboembolic pulmonary hypertension (CTEPH) has traditionally been considered a long-term complication of pulmonary embolism. However, a substantial proportion of patients have no history of venous thromboembolism (VTE), suggesting underlying biological heterogeneity. METHODS: We analyzed clinical and imaging characteristics of 712 patients with CTEPH stratified by prior VTE history. Whole-genome sequencing was performed in all patients and 2952 healthy controls to assess common variants. Bulk RNA sequencing of pulmonary endarterectomy tissues and plasma protein quantification were integrated to identify and validate subgroup-specific molecular signatures, with further validation in tissue and primary endothelial cells. RESULTS: Patients with CTEPH and prior VTE (n=576, 80.9%) exhibited a distinct thrombotic phenotype with more proximal disease distribution (92.5% versus 66.2%) and greater likelihood of undergoing pulmonary endarterectomy (22.6% versus 3.7%). Genome-wide association study in CTEPH-VTE(+) patients versus controls identified coagulation-related loci at ABO (rs676996, P =1.1×10 –9 ) and FGG (rs7681423, P =2.5×10 –8 ), with high genetic correlation with pulmonary embolism (rg=0.52, P =0.028). In contrast, no consistent genomic signal was identified in patients without prior VTE. Integrative multiomics (transcriptome-wide association study, MAGMA, and bulk RNA sequencing differential expression analysis) convergently prioritized CTSS (cathepsin S) as a key molecular candidate in CTEPH-VTE(+). CTSS was consistently elevated in plasma, pulmonary endarterectomy tissue, and primary endothelial cells from CTEPH-VTE(+) patients and promoted endothelial proliferation via ERK signaling, which was attenuated by the selective CTSS inhibitor LY3000328. CONCLUSIONS: Stratification by prior VTE history reveals biologically distinct CTEPH phenotypes with divergent genetic architectures and identifies cathepsin S as a genetically nominated therapeutic target for thrombosis-associated pulmonary vascular remodeling.

  • Open Access

    ABCB1 genotype and clinically relevant bleeding risk during extended anticoagulation therapy for pulmonary embolism: a two-phase study

    by Zhu Zhang, Haobo Li, Bingzhang Zou, Xiaofan Ji, Yu Zhang, Yuzhi Tao, Linfeng Xi, Kuangxun Li, Huiwen Li, Mengjie Duo, et al.

  • Open Access

    Predictive Power of Pulmonary Artery Stiffness—Right Ventricular Interplay, But Not Pulmonary Vascular Resistance, in Mild Pulmonary Hypertension

    by Athiththan Yogeswaran, Meike Fünderich, David G. Kiely, Jeffrey S. Annis, Evan Brittain, Harm Jan Bogaard, Aparna Balasubramanian, Paul M. Hassoun, Luke Howard, Allan Lawrie, et al.

  • Ambient temperature, air pollutants, and pulmonary embolism onset: a 17-year nationwide study in China

    by Lu Zhou, Mengjie Duo, Bingzhang Zou, Zhu Zhang, Hong Chen, Yuanhua Yang, Jun Wan, Xiaomao Xu, Yingqun Ji, Guoru Yang, et al.


  • Open Access

    Perceptions, Responsibility, and Implementation of AI-CDSS in VTE Prevention: A Qualitative Study (Preprint)

    by Zhu Zhang, Zhenguo Zhai, Zhaofei Chen, Yunfan Shi, Mengyao Li, Ying Tang, Jingrui Li, Liangfeng Zhu, Yanmin Li, Jingyong Xue, et al.

    BACKGROUND Background: Artificial intelligence–enabled clinical decision support systems (AI-CDSSs) are increasingly deployed for venous thromboembolism (VTE) prevention. However, healthcare professionals’ perceptions and experiences of these systems across diverse regional, occupational, and specialty contexts remain poorly understood, with limited evidence on how AI integration influences clinical workflows, responsibility allocation, and professional trust within multi‑tiered healthcare systems. OBJECTIVE Objective: This study aimed to systematically investigate healthcare professionals’ perceptions and experiences of using AI-CDSS for VTE prevention across different institutional levels and clinical roles in China. METHODS Methods: A nationwide qualitative study was conducted using semi‑structured interviews with 23 healthcare professionals from diverse institutional levels and clinical roles. Data collection proceeded until thematic saturation was reached. All interviews were transcribed verbatim and analyzed using inductive thematic analysis. RESULTS Five core themes were identified: (1) AI reduces workload but complicates clinical responsibility; (2) patient involvement is perceived as beneficial yet problematic; (3) digital readiness shapes implementation feasibility; (4) trust in AI varies by professional role; and (5) responsibility and risk remain ambiguous after AI introduction. Facilitating factors included clearly defined responsibility assignment, comprehensive training, incentive mechanisms, and institutional oversight. Key barriers comprised economic costs, additional workload burden, and complex hospital approval processes. CONCLUSIONS Our findings reveal structural tensions arising from the interaction between professional roles, institutional readiness, and responsibility distribution during AI integration. These results underscore the need for tiered, role‑specific implementation strategies and provide practical insights for the sustainable deployment of AI in VTE prevention.